Stockscreener 앱 받기
46.23
1.95%
-0.94
전일 마감가:
$47.17
열려 있는:
$45.87
하루 거래량:
6.25M
Relative Volume:
0.51
시가총액:
$202.65B
수익:
$50.91B
순이익/손실:
$18.95B
주가수익비율:
10.85
EPS:
4.261
순현금흐름:
$1.92B
1주 성능:
+3.87%
1개월 성능:
-6.52%
6개월 성능:
-5.47%
1년 성능:
-7.09%
1일 변동 폭
$45.56
$46.30
1주일 범위
$44.93
$47.73
52주 변동 폭
$35.12
$64.16
노보 노디스크 Stock (NVO) Company Profile
Compare NVO vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
46.26 | 206.66B | 50.91B | 18.95B | 1.92B | 4.261 |
LLY
Lilly Eli Co
|
1,221.43 | 1.08T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
260.88 | 626.09B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
248.24 | 441.94B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
133.68 | 321.77B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
152.65 | 293.87B | 54.66B | 13.58B | 16.05B | 7.0171 |
노보 노디스크 Stock (NVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-26 | 개시 | Wolfe Research | Peer Perform |
| 2026-03-18 | 개시 | Bernstein | Outperform |
| 2026-03-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2026-03-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2026-03-02 | 다운그레이드 | Goldman | Buy → Neutral |
| 2026-02-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2026-02-24 | 다운그레이드 | Kepler | Buy → Hold |
| 2026-02-23 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2026-02-12 | 업그레이드 | Jefferies | Underperform → Hold |
| 2026-01-27 | 개시 | Citigroup | Neutral |
| 2025-12-08 | 다운그레이드 | Argus | Buy → Hold |
| 2025-10-27 | 재개 | Jefferies | Underperform |
| 2025-10-01 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2025-09-29 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2025-09-16 | 업그레이드 | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | 업그레이드 | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-31 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-07-30 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-04-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | 업그레이드 | Kepler | Hold → Buy |
| 2025-03-03 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-02-12 | 개시 | Morgan Stanley | Equal-Weight |
| 2025-01-06 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-12 | 개시 | BMO Capital Markets | Outperform |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Neutral |
| 2023-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-02 | 개시 | Argus | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2022-07-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-06-27 | 업그레이드 | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-05-31 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-04-25 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2022-04-12 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-01-25 | 다운그레이드 | Liberum | Hold → Sell |
| 2021-12-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-12-17 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-01-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-07-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-05-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-05-04 | 개시 | Cowen | Market Perform |
| 2020-03-16 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-11-18 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-09-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-30 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2019-06-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-06-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2019-04-29 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | 개시 | Exane BNP Paribas | Outperform |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2017-12-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-12-06 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
모두보기
노보 노디스크 주식(NVO)의 최신 뉴스
Why Does Novo Nordisk (NYSE:NVO) Matter to S&P 500 Healthcare? - Kalkine Media
Novo Nordisk A/Sshare repurchase programme - Finansavisen
EBITDA per share of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVO.CI - TradingView
Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B Revenue Breakdown – BCBA:NVO.CI - TradingView
Novo Nordisk Share Price Forecast | Q2 Earnings, Raised Guidance - Capital.com
Novo Nordisk NVO stock prediction: $64 bull vs $32 bear - FinanceFeeds
Novo Nordisk (CPH:NOVO-B; NYSE:NVO) ADR drops after Q2 results outpace forecasts, paving way for possible rebound in Copenhagen - TechStock²
Novo Nordisk reports adjusted operating profit of DKK 33,389 million for Q2 2026 and raises full-year outlook - Finansavisen
Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026 - Finansavisen
Novo Nordisk (NYSE: NVO) updates DKK 7,533,256,457 share repurchases - Stock Titan
Novo Nordisk (NYSE:NVO) Ziltivekimab Trial Fails In Late Stage Cardiovascular Study - Sahm
Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation - Finansavisen
Novo Nordisk shares fall after ZEUS trial disappointment highlights 94% sales reliance - TechStock²
ETFs Investing in Novo Nordisk A/S Sponsored ADR Class B Stocks - TradingView
Novo Nordisk A/S Sponsored ADR Class B Revenue Breakdown – MUN:NOVA - TradingView
Europe’s US-Listed ADRs Edged Higher Late Friday Morning - Finimize
Market news - investments.halifax.co.uk
2 Top Growth Stocks to Buy Right Now Without Any Hesitation - The Motley Fool
BR:N1VO34 Stock Latest News - TipRanks
NVO Stock Quote Price and Forecast - CNN
Novo Nordisk Sues Eli Lilly Over Alleged Deceptive Weight Loss Drug Advertising - Sahm
Novo Nordisk A/S ADR (NVO-N) Stock Price and News - The Globe and Mail
Novo Nordisk (NYSE: NVO) reports 24,959,179 shares repurchased in 2026 programme - Stock Titan
Novo Nordisk's Steady Innovation in Diabetes and Obesity Have Created a Wide Moat - Morningstar
Novo Nordisk (NYSE:NVO) Wins EU Approval For Oral And Higher Dose Wegovy - Sahm
Wegovy Pill in EuropeNovo Nordisk Expands Franchise With First European Approval for Oral Weight Loss Drug - Sahm
NVOH ETF Profile: Dividends, Returns (AMEX:NVOH) - TradingView
Novo Nordisk (NVO) Stock May Be 50% Undervalued Despite Medicare GLP 1 Coverage - Sahm
Novo Nordisk (NYSE:NVO) Updates Wegovy Label In Singapore With 21% Weight Loss Data - Sahm
Total equity of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVOD - TradingView
Weekly Recap: NOVO_B MAR buyback and Shares jump after UK Wegovy approval - TradingView
노보 노디스크 (NVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.64%
0.09%
자본화:
|
볼륨(24시간):